The Korean Journal of Internal Medicine

Search

Close

Case Report
Korean J Med. 2026;101(5):272-277. Published online October 1, 2026.
DOI: https://doi.org/10.3904/kjm.2026.101.5.272
피마사르탄 재복용 및 간 생검으로 확인된 약인성 간 손상 1예
김세령1, 이지수2, 진수지3, 김상균4, 김영석4, 유정주4
1순천향대학교 천안병원 의학과
2순천향대학교 부천병원 내과
3순천향대학교 부천병원 병리과
4순천향대학교 부천병원 소화기내과
A Case of Fimasartan-Induced Liver Injury Proven by Rechallenge and Biopsy
Seryeong Kim1, Jisoo Lee2, Susie Chin3, Sang Gyune Kim4, Young-Seok Kim4, Jeong-Ju Yoo4
1Department of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea
2Departments of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
3Departments of Pathology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
4Division of Gastroenterology and Hepatology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
Corresponding author: Jeong-Ju Yoo ,Tel: +82-32-621-5215, Fax: +82-32-621-6079, Email: puby17@naver.com
Received: October 30, 2025; Revised: January 19, 2026   Accepted: January 24, 2026.
¿ä¾à


Á߽ɾî :약인성 간손상; 간염; 안지오텐신 수용체 차단제; 생검
Abstract
Fimasartan is a widely used angiotensin II receptor blocker (ARB) known for its favorable safety profile. However, its hepatotoxic potential remains poorly characterized. We report a case of drug-induced liver injury (DILI) in a 79-year-old woman who developed jaundice and elevated liver enzymes after initiating fimasartan. Liver biopsy revealed severe lobular hepatitis with confluent necrosis. Liver function normalized following drug discontinuation and corticosteroid therapy; however, the injury recurred after accidental reexposure to fimasartan and resolved again upon withdrawal. This temporal association and recurrence upon rechallenge allowed for a definitive diagnosis, with a Roussel Uclaf causality assessment method score of 12 indicating “highly probable” causality. Although ARBassociated DILI is uncommon, this case highlights the need for clinicians to remain vigilant regarding the potential hepatotoxicity of fimasartan. Clinicians should monitor liver function closely during treatment and consider alternative agents if injury occurs.

Keywords :Chemical and drug induced liver injury, Hepatitis, Angiotensin receptor antagonists, Biopsy
ics samyangbiopharm Hanmi
yungjin

Go to Top